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Abstract
Background: Proteolytic degradation of Type I Collagen by proteases may play an important role in remodeling of 
atherosclerotic plaques, contributing to increased risk of plaque rupture.
The aim of the current study was to investigate whether human macrophage foam cells degrade the extracellular
matrix (ECM) of atherosclerotic plaques by cathepsin K mediated processes.
Methods: We 1) cultured human macrophages on ECM and measured cathepsin K generated fragments of type I 
collagen (C-terminal fragments of Type I collagen (CTX-I) 2) investigated the presence of CTX-I in human coronary 
arteries and 3) finally investigated the clinical potential by measuring circulating CTX-I in women with and without 
radiographic evidence of aortic calcified atherosclerosis.
Results: Immune-histochemistry of early and advanced lesions of coronary arteries demonstrated co-localization of 
Cathepsin-K and CTX-I in areas of intimal hyperplasia and in shoulder regions of advanced plaques. Treatment of 
human monocytes with M-CSF or M-CSF+LDL generated macrophages and foam cells producing CTX-I when cultured 
on type I collagen enriched matrix. Circulating levels of CTX-I were not significantly different in women with aortic 
calcifications compared to those without.
Conclusions: Human macrophage foam cells degrade the atherosclerotic plaques though cathepsin K mediated 
processes, resulting in increase in levels of CTX-I. Serum CTX-I was not elevated in women with aortic calcification, likely 
due to the contribution of CTX-I from osteoclastic bone resorption which involves Cathepsin-K. The human 
macrophage model system may be used to identify important pathway leading to excessive proteolytic plaque 
remodeling and plaque rupture.
Background
Worldwide, cardiovascular disease (CVD) is the leading
cause of morbidity and mortality[1]. Atherosclerosis, the
underlying cause of CVD events, is a complex and life-
long process which leads to the development of intimal
fatty streaks and more complex lesions which may go
unnoticed for decades prior to clinical events such as a
myocardial infarction. The main event leading to clini-
cally significant disease often involves the rupture of
unstable atherosclerotic lesions.
Collagen turnover is mediated by both matrix metallo-
proteinases (MMPs) and cathepsins[2]. MMPs have
hereto been considered to be the proteases of paramount
importance in the atherosclerotic plaques[3,4], however
recent research has identified other proteases such as
cathepsins and aggrecanasess [5-17] as equally impor-
tant. This emerging line of evidence demonstrating that
extensive proteolytic activity of different origins is of par-
amount important of the pathogenesis of atherosclerosis,
further emphasis the need for understanding the role of
the proteolytic array of enzymes in the remodeling of the
extracellular matrix of the atherosclerotic plaques. Cathe-
psin K is a lysosomal protease predominantly secreted by
activated macrophages[18] and osteoclasts[19,20]. Cathe-
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and in differentiated macrophages[5-7,11], such as epi-
thelioid cells and multinucleated giant cells in soft tis-
sues[22]. Moreover, disruption of the cathepsin K gene
reduces atherosclerosis progression suggesting the prote-
olytic activity of cathepsin K to be important for the
pathogenesis of atherosclerosis[10].
Tissue turnover may be assessed by biochemical mark-
ers of tissue degradation[23,24]. Biochemical markers of
tissue turnover are increasingly used in both basic and
clinical research, for diagnostic, prognostic and efficacy
purposes[24,25]. In addition, such markers may provide
additional information for understanding the pathology
of disease. Proteolytic degradation of ECM molecules by
proteases such as cathepsins and matrix-metallo protei-
nases results in the generation of small protein degrada-
tion fragments, neo-epitopes. The collagen turnover in
the plaques is primary caused by an increased degrada-
tion of collagen type I, which accounts for approximately
60-70% of total collagen in artery[26]. Cathepsin K is the
major protease of osteoclasts, responsible for bone
resorption[27]. The protease activity of cathepsin K on
collagen type I results in a specific degradation fragment,
CTX-I (C-terminal telopeptide of collagen type I)[23,28].
This fragment has been extensively used as a surrogate
measure of bone resorption for in vitro, preclinical and
clinical studies[23,29].
The aim of the current studies was to investigate
whether macrophages degraded the articular matrix
through processes involving cathepsin K and collagen
type I. We examined 1) The expression and localisation of
cathepsin K in atherosclerotic plaques, 2) the ability of
human macrophage foam cells to generate CTX-I frag-
ments in culture and finally 3) to investigate whether
these molecular processes were of clinical significance,
we assessed the relationship between the circulating lev-
els of CTX-I molecules and aortic calcification in patients
with radiological detectable aortic calcifications.
Methods
Sample material for immune-histochemistry
Arterial tissues from two subjects with and without a his-
tory of CVD were investigated by immune-histochemis-
try. Samples were collected 0.15-20 cm distal to the origin
of the left descending coronary artery (LAD). The first
subject (subject A) was a 77 yr female with an advanced
atherosclerotic plaque (cross-sectional area of plaque size
was 6.2 mm2). The second subject (subject B) was a 32 yr
female with a minimal atherosclerotic lesion of 0.2 mm2.
Sample collection and handling was performed post-
mortem in accordance with the guidelines of the medical
ethical committee of the Wake Forest University Health
Sciences as previously described[30].
Serum samples
For the clinical investigation, subjects were selected from
a previously reported epidemiological study of 1356
elderly women aged 60 to 85 years examined at the Cen-
ter for Clinical and Basic Research, Denmark[31]. Briefly,
the participants in the present study were recruited by
questionnaire surveys. In 2000 to 2001, these women
were invited for a follow-up examination. All women gave
informed consent to participation, and the study was car-
ried out in accordance with the Helsinki Declaration II
and the European Standards for Good Clinical Practice.
The local ethics committee approved the study protocol.
Participants in the present investigation were 102
women, including 51 women diagnosed with CVD and 51
age-matched controls. The CVD diagnosis was based on
the presence of calcified deposits in the lumbar aorta
visualized on lateral radiographs and graded with scores
ranging from 0 to 24. Calcified deposits in the lumbar
aorta adjacent to each lumbar vertebra (L1-L4) were
assessed separately for the anterior and posterior wall of
the aorta using the midpoint of the inter-vertebral space
as the boundaries. Severity of aortic calcifications was
described by 3 scores: the affected segments score (scale
0 to 4), the anterior and posterior affected score (scale 0
to 8), and the anteroposterior severity score (scale 0 to
24)[32]. Women graded with a score of 8 or more were
classified as having CVD in the present investigation.
Additional CVD risk factors were collected. Body weight
and height were measured and BMI calculated. Arterial
blood pressure was measured with a digital blood pres-
sure monitor (UA-777, A&D Instruments LTD). Total
cholesterol and triglyceride levels were measured by a
Vitros-250 automatic blood analyzer (Johnson & John-
son). All serum samples were collected in the morning
from fasted individuals. Demographic characteristics in
the study population are indicated in Table 1.
Immunohistochemistry
Hearts were perfusion fixed at 100 mm Hg with formalin,
coronary arteries were isolated, blocks were paraffin
embedded, sectioned into 5 μM sections and mounted on
glass. Pretreatment of sections in buffer 1 (10 mM Tris,
0.25 mM EDTA, pH 9.0) was used to enhance epitope
presentation. The sections were blocked for nonspecific
binding in Tris buffered saline (TBS) containing 5%
casein before incubation with a monoclonal antibody to
human CTX-I (in-house) or mouse anti-human Cathep-
sin K (Chemicon, MAB3324 directed against a synthetic
peptide corresponding to amino acids 182-195 of human
cathepsin K) or rabbit polyclonal antiserum LF-9 against
Bovine alpha1(I) amino-propeptide of Collagen I with
cross-reactivity to human, monkey pig and sheep (Larry
W Fisher, Matrix Biochemistry Section, Cranofacial and
skeletal diseases branch, NIDCR/NIH, Bethesda, Mary-
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(DAKO cytomation, DK) was used as secondary anti-
body. Immunoreactivity was visualized by liquid DAB
substrate chromogen solution (3,30-diaminobenzidine
chromogen). The nuclei were counterstained using
hematoxylin (DAKO), and the slides were dehydrated,
cleared and cover-slipped. Digital histographs were taken
using an Olympus BX60 microscope and an Olympus
CP71 camera.
Cell culture
Isoltion of CD14+ primary monocytes was performed
using coated Dynabeads M-450 (111.11 Dynal Biotech).
Human monocytes were isolated from peripheral blood
from healthy female volunteers 18 to 45 years old. The
blood was diluted 1:1 with PBS (BE17-512F Biowhit-
taker), carefully layered on a Ficoll-Paque gradient (17-
1440-03 Amersham Pharmacia) and centrifuged at 2000
rpm for 20 minutes. The lymphocytes were collected
from the interface between the plasma and the Ficoll-
Paque, washed with ice-cold PBS followed by centrifuga-
tion at 2000 g rpm for 12 minutes. The wash was repeated
twice, after which the cells were re-suspended in cold PBS
containing 2% serum (S0415 Biochrom). The cells were
kept on ice while the beads were prepared. 125 μl CD14+
magnetic beads (10 million beads) were washed 3 times
in ice cold PBS. The beads were placed in the magnetic
device for 2 minutes between each wash.
Three hundred million cells were added to the beads
and incubated at 4°C with end-over-end homogenization
for 20 minutes. Hereafter, the beads were washed 5 times
in 5 ml PBS containing 2% serum with gentle re-suspen-
sion between each washing step. Finally, the cells were re-
suspended in phenol-red free alpha-MEM containing
10% serum, 100 units/ml penicillin and 100 μg/ml strep-
tomycin, as previously described[20,33].
To generate human monocyte-macrophage cultures,
the CD-14 positive cells were cultured in 75 cm2 bottles
in phenol-red free alpha-MEM containing 10% serum,
100 units/ml penicillin, 100 μg/ml streptomycin, 25 ng/
ml M-CSF for 3 days. Cells were released using trypsin
and replated on 48,8% Matrigel®Basement Membrane
Matrix (cat.no 40234, lot no. 900618) from Engelbreth-
Holm-Swarm (EHS) mouse tumor rich in ECM proteins.
Major component of the Matrigel is laminin, followed by
collagen IV, heparin sulfate proteoglycan, entactin and
nidogen. In our experiments, Matrigel was enriched with
41,5% type I collagen (3 mg/mL), 4,9% 10 × alpha-MEM
and 4,9% reconstitutions buffer. After one day allowing
the cells to incorporated into the matrix the cells were
incubated in either absence (macrophages) or presence
(foam cells) of 2 mg/ml LDL (L8292 Sigma-Aldrich) and
M-CSF, and with or without selective cysteine protease
inhibitor E64 (Calbiochem). Following the culture, cells
were fixed in 4% formaldehyde, and stained for lipid
droplets by oil red staining. Medium was collected for
assessment of the presence of CTX-I indicative of cathep-
sin K mediated type I collagen degradation.
Biochemical Analysis
Serum samples were analyzed for degradation fragments
of the C-telopeptides of type I collagen by the Serum
CrossLaps ELISA (Nordic Bioscience, Denmark). Briefly,
the Serum CrossLaps ELISA is based on monoclonal
Table 1: Characteristics of the study population stratified into women with CVD and the control group.
Control (n = 51) Disease (n = 51) p-value
Age (years) 73.6 ± 0.6 73.5 ± 0.6 0.9079
Triglyceride (mmol/L) 1.35 ± 0.07 1.72 ± 0.13 0.0158 *
BMI (kg/m2) 26.8 ± 0.5 26.7 ± 0.5 0.8222
Systolic BP (mm Hg) 148.9 ± 3.8 147.3 ± 3.2 0.7547
Diastolic BP (mm Hg) 82.0 ± 1.7 78.2 ± 1.6 0.1087
Total cholesterol (mmol/L) 6.53 ± 0.14 6.13 ± 0.20 0.1052
Aortic calcification 0 12.6 ± 0.51
Results shown are mean ± SEM unless otherwise indicated.
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sequence EKAHD-β-GGR specific for the C-telopeptide
of type I collagen and D-β-G representing the isomerised
bond between aspartate and glycine. The sandwich assay
which detects cross-linked peptides (CTX-I), has been
reported to have intra-assay and inter-assay coefficient of
variation of 4.9% and 7.9%, respectively and is useful for
the quantitative assessment of bone resorption[34].
Statistics
Results shown are mean ± SEM. Significant differences
between means of study groups were determined using
the Student's two-tailed unpaired t-test. Differences were
considered statistically significant if p < 0.05.
Results
Cathepsin K and CTX-I are expressed in advanced but not 
early lesions
Left anterior descending (LAD) coronary arteries with
different degrees of atherosclerotic lesions were assessed
for the expression and localization of collagen type I,
cathepsin K and the CTX-I cleavage product of type I col-
lagen, generated by the action of cathepsin K (Figure 1).
Immune-histochemical analysis revealed co-localization
of collagen type I and cathepsin K in the advanced ath-
erosclerotic lesions, especially at the plaque shoulders
(Figure 1 D1 and 1 E1). In close proximity to the cathep-
sin staining there was a corresponding accumulation of
CTX-I, presumably resulting from the cathepsin K activ-
ity on collagen type I. In the relatively unaffected coro-
nary arteries there was little or no positive staining for the
cathepsin K and CTX-I (Figure 1 A1, B2 and 1 C1).
Human monocyte-macrophage foam cells generate CTX-I 
fragments when cultured on collagen type I-rich matrix
Human monocyte-macrophage cultures were generated
using CD-14 positive monocytes cultured on plastic in
the presence of M-CSF or M-CSF in combination with
LDL. When incubated in the presence of LDL, cells
assumed a foam cell like appearance and were oil red pos-
itive as illustrated on Figure 2.A and 2.B.
To investigate whether these cells were able to degrade
a collagen-rich ECM in part resembling that of the arte-
rial wall, human monocyte-macrophages were generated
and cultured on a matrigel (MG) enriched with 48.8% col-
lagen type I. Collagen type I degradation by cathepsin K
was measured by assessing the appearance of CTX-I in
the conditioned medium after the culture period[23]. As
presented in Figure 3A, macrophages (MF) alone did not
generate CTX-I fragments above lowest detection limit of
the assay. MG alone released to a lesser amount CTX-I
fragments. In contrast, MF cultured on MG released 100-
fold (p < 0.01) more cathepsin K generated collagen type I
fragments (CTX-I), relative to control (matrigel alone).
We also assessed the amount of CTX-I released when
culturing monocytes in the presence of 2 mg/ml of LDL.
Additionally, we also tested the levels of CTX-I released,
when cells were cultured in the presence of selective
cysteine protease inhibitor - E64. As illustrated in Figure
3B foam cells (FC) did not release any considerable
amount of CTX-I when cultured on plastic. Matrigel
(MG) released to a lesser amount CTX-I to the culture
medium. FC cultured on matrigel released 30-fold (p <
0.01) increased levels of CTX-I relative to MG control.
The cysteine protease inhibitor E64, resulted in a similar
amount of CTX-I released as in MG control. All cell cul-
ture experiments have been validated for cell viability by
Alamar blue (data not shown).
No difference in serum levels of CTX-I in patients and 
control subjects
Women assigned to the CVD group based on radio-
graphic evidence of aortic calcification had calcification
scores between 9 and 24, with an average of 12.6 ± 0.5.
This group had higher plasma triglyceride concentrations
(p = 0.016) than age-matched control group with no aor-
tic calcification did not differ in systolic blood pressure or
total plasma cholesterol, (Table 1).
We assessed serum CTX-I levels in this population to
determine if levels might be elevated in subjects with aor-
tic calcification relative to those without, perhaps as evi-
dence of extensive vascular degradation of type I
collagen.
The level of CTX-I was found to be significantly lower
in patients with CVD (0.35 ± 0.03 ng/ml) compared to the
control group (0.46 ± 0.03 ng/ml), p = 0.014 as presented
on Figure 4. Exclusion of individuals receiving anti-
resorptive osteoporosis treatments such as bisphospho-
nates and hormone replacement therapies which lower
CTX-I levels by approximately 50% eliminated these dif-
ferences (0.40 ± 0.04 ng/ml patient group (n = 31), vs.
0.50 ± 0.03 ng/ml (n = 43) control group, p = 0.061). (Fig-
ure 4)
Discussion
Extracellular matrix remodelling is an important process
in atherosclerotic plaque turnover and stability. To our
knowledge, we are the first to demonstrate that mac-
rophage foam cells generate CTX-I when cultured on col-
lagen type-I rich matrix, providing biological rationale for
the co-localisation of CTX-I and cathepsin K in the
advanced atherosclerotic lesions.
CTX-I is one of the fragments generated through enzy-
matic cleavage of collagen type I by cathepsin K[35]. We
demonstrated strong positive staining of both cathepsin
K and CTX-I in coronary arteries with advanced athero-
sclerotic plaques in comparison to normal coronary
arteries, where cathepsin K staining was very weak.
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Figure 1 Immunohistochemical staining of Collagen type I, Cathepsin K, and CTX-I in: early and advanced lesions. A, B and C: staining of Col-
lagen type I, Cathepsin K and CTX-I, respectively in an early lesion. D, E and F: staining of Collagen type I, Cathepsin K and CTX-I, respectively in an 
advanced lesion. A1, B1, C1, D1, E1 and F1 are 2× magnified, whereas A2, B2, C2, D2, E2 and F2 are 10 × magnified. Brown colouring suggest positive 
staining with the particular antibody, whereas blue staining suggest Hematoxyllin staining of the cell nuclei.
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ously seen by Lutgens et al[10], demonstrating cathepsin
K mRNA expression at low levels in early atherosclerotic
lesions which were up-regulated in advanced lesions by
up to 28 fold.
As collagen I constitutes 60-70% of the matrix content
in arteries[36], we hypothesized that the level of CTX-I
would be high [37] in advanced atherosclerotic lesions.
Our results from immune-histological stainings of
human coronary arteries confirmed this hypothesis and
furthermore showed a co-localization of CTX-I and
Cathepsin K in the advanced lesion.
To further investigate the biological origin of CTX-I in
the advanced atherosclerotic lesions, human macrophage
foam cells were generated and cultured on a type I colla-
gen enriched matrix. We used the CD-14 positive selec-
tion procedure to have a pure hematopoietic stem cell
population, that our group extensively has investi-
gated[19,20]. The aim of these experiments was to inves-
tigate whether macrophages and foam cells were able to
generate cathepsin K mediated type I degradation prod-
ucts (CTX-I). The role of cathepsin K and foam cells in
atherosclerosis has been demonstrated by oth-
ers[6,7,9,10,21]. We have previously published extensively
on the use of osteoclasts and CTX-I[35,38,39], and the
use of this hematopoietic cell culture system in bone biol-
Figure 2 Culturing of human monocytes and macrophage foam 
cells. CD-14 monocytes were isolated and cultured on plastic for 14 
days in the presence of either M-CSF alone (Panel A) or M-CSF and 2 
mg/ml LDL (Panel B). After the culture, cells were fixed in 4% formalde-
hyde, and stained for lipid droplets by oil red staining. Monocyte-mac-
rophages cultured in the presence of LDL assumed the appearance of 
foam cells and were oil-red O positive.
Figure 3 Cell cultures. A) Human monocyte-macrophages and B) 
macrophage-foam cells (FC) were generated and cultured on a matri-
gel (MG) enriched with 48.8% collagen type I, with or without Cathep-
sin K inhibitor E64. Collagen type I degradation was measured by CTX-
I assay in the conditioned medium after the culture period.
Figure 4 Levels of CTX-I measured in blood samples for control-
group (CD = 0) and disease group (CD = 1).
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ture, CTX-I was generated by cathepsin K[20,38,41]. This
correlated with an increased cathepsin K expression as
previously shown [20,33].
The results from the human macrophages and mac-
rophage foam cell cultures clearly demonstrate that
human macrophage foam cells produce cathepsin K frag-
ments of collagen type I, the CTX-I. This is to our knowl-
edge this first data describing a simple model system in
which human macrophage foam cell mediated degrada-
tion of the extra cellular matrix can be monitored. This
assay may be used to identify treatments that will modu-
late the macrophage foam cell degradation of the matrix,
by enzymes such as cathepsin K and thus aid in the iden-
tification of novel treatments that will attenuate athero-
sclerotic plaque turnover and subsequently prevent
rupture of the unstable plaques.
The measured cathepsin K activity, in form of the gen-
erated CTX-I fragment, may arise from both secreted
cathepsin K and the cathepsin K in lysosomes. Osteo-
clasts, a different phenotype of macrophages, have previ-
ously been shown to transcytose collagen type I and
degraded type I collagen (CTX-I) during bone degrada-
tion - and as macrophages are phagocytic cells, a similar
pathway involving intracellular lysosome mediated colla-
gen type I degradation may be responsible[42,43]. Fur-
ther research is needed to differentiate and understand
biological differences between these distinct forms of
proteolytic activities sequestered in the matrix or lyso-
somal degradation.
Circulating levels of CTX-I were not elevated in the
population of largely post-menopausal women suffering
from CVD. This observation is likely explained by the
dominating contribution of CTX-I derived from bone-
resorption [44] which would be expected to be relatively
high in post-menopausal women not on anti-resorptive
therapies. This is supported by the observation that
exclusion of the sub-group of women receiving hormone
and osteoporosis treatment abolished apparent differ-
ences in the circulating CTX-I levels between the groups.
Anti-osteoporosis treatment are known to lower CTX-I
levels by approximately 50%, explaining this observa-
tion[23]. Local proteolytic events in the atherosclerotic
plaques seem to be associated with plaque instability and
plaque rupture, and not directly with the amount of arte-
rial calcification. However, as the number and extend of
calcifications are directly proportional to the ODDs ratio
of experiencing a CVD event, there might be an indirect
relation[45]. Arterial calcification is an end-stage of
actively remodeling plaques, which either results in rup-
ture or become stable plaques.
The group of patients with diagnosed CVD had an
average AC-score of 12.6. We demonstrated significantly
higher levels of triglyceride in CVD-group compared to
the control group. As shown by previous studies there is a
correlation between the level of triglyceride and the risk
of CVD [46-49]. Thus, even though that the patient pop-
ulation may be appropriate for detecting an increased
level of CTX-I related to the arterial pathogenesis, this
was not possible, which most likely is due to the contribu-
tion of bone related CTX-I to the systemic pool.
One limitation of the current study is the variation in
induction of the amount of CTX-I generated in cultures
with macrophages and macrophage-foam cells. These
variations are most likely due to experimental variation of
batch numbers of proteins and matrigel, as well as varia-
tion in cell number. Further research is needed for
obtaining a more robust system, which will allow for
careful investigation of pathophysiological processes
mediated by macrophages.
Conclusions
In conclusion, our data suggest, that CTX-I might be a
specific marker of pathophysiological processes involved
in the extracellular remodeling of plaques. Cathepsin K
and CTX-I were absent from early human atherosclerotic
lesions while being present in advanced lesions, suggest-
ing this class of biomarkers as useful tools for diagnosing
and staging of the atherosclerotic lesions. The herein
described assay and techniques may aid others research-
ers in the identification of important pathways leading to
increased levels of proteolytic activity on macrophages,
and thus progress the development of the identification
of novel treatment of atherosclerosis.
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